Physician profile
Robert E Andrews
NPI 1609849793
$1,480.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $413 · 2021: $430 · 2022: $194.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $544.14 | 2019-2022 | |
| Abbott Laboratories | $384.65 | 2019-2022 | |
| Si-Bone, INC. | $105.16 | 2019-2021 | |
| Nalu Medical, INC. | $87.21 | 2021-2022 | |
| Medtronic USA, INC. | $86.57 | 2019 | |
| Allergan, INC. | $78.74 | 2019-2020 | |
| Nevro Corp. | $49.44 | 2019-2022 | |
| Amgen INC. | $42.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.09 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.94 | 2019 | |
| Merz North America, INC. | $13.34 | 2020 | |
| Biodelivery Sciences International, INC. | $12.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.